NEW BRUNSWICK, N.J., Dec. 14, 2010 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research today opens its 2011 call for nominations. This prestigious award recognizes individuals whose scientific research has made, or has the potential to make, significant transformational contributions toward the improvement of human health. Nominations are available at www.pauljanssenaward.com and will be accepted until February 15, 2011, for consideration by an independent selection committee of world renowned scientists. The winner or winners will receive a $100,000 cash prize.
The Dr. Paul Janssen Award for Biomedical Research honors Dr. Paul Janssen (1926-2003), who is widely recognized as one of the most productive scientists of the 20th century. Known by colleagues throughout the scientific community as “Dr. Paul,” Janssen was responsible for breakthrough treatments in disease areas including pain management, psychiatry, infectious disease and gastroenterology and founded Janssen Pharmaceutica, N.V., a Johnson & Johnson Company.
“The Dr. Paul Janssen Award for Biomedical Research recognizes outstanding scientists whose work is game-changing in the development or delivery of critical new treatments and exemplifies Dr. Paul’s passion for medical innovation,” said Paul Stoffels, M.D., global head, Research & Development, Pharmaceuticals, Johnson & Johnson, who worked for many years alongside Dr. Janssen.
In September 2010, the Award was presented to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) and Erik De Clercq, M.D., Ph.D., chairman of the Department of Microbiology and Immunology of the Medical School at the Catholic University of Leuven. Dr. Fauci received the Award for his ground-breaking contributions to basic and clinical research in the areas of AIDS and other immunodeficiencies. Dr. De Clercq was recognized for his landmark discoveries in anti-HIV medications, including nucleotide analogues, and inventions or co-inventions of six approved drugs for anti-viral therapy.
Previous Award winners include Axel Ullrich, Ph.D., director, Department of Molecular Biology, Max Planck Institute of Biochemistry in Germany; Professor Marc Feldmann, FMedSci, FAA, FRS, and Emeritus Professor Sir Ravinder Maini, FRCP, FMedSci, FRS, of the Kennedy Institute of Rheumatology, Imperial College London; and Craig Mello, Ph.D., Nobel Laureate, of the Howard Hughes Medical Institute and University of Massachusetts Medical School.
“Scientists across the globe work tirelessly to achieve significant and lasting contributions to improving health and well being,” said Harlan Weisman, M.D., chief science and technology officer, Medical Devices & Diagnostics, Johnson & Johnson. “In acknowledging and rewarding those contributions, The Dr. Paul Janssen Award inspires us all to embody the scientific passion, compassion and leadership for which Dr. Paul was so well loved and respected.”
Beyond the passion and creativity Dr. Paul demonstrated in the laboratory, he also inspired and mentored many young scientific leaders who went on to great achievements in addressing medical need.
“As in past years, we look forward to selecting a 2011 Dr. Paul Janssen Award winner from among the nominations of worthy individuals in research institutions and companies around the world, who has significantly improved human health through dedication to the advancement of science and medicine,” said Solomon Snyder, Ph.D., distinguished service professor of neuroscience, pharmacology and psychiatry, Johns Hopkins School of Medicine and 2011 chair of the Dr. Paul Janssen Award Selection Committee.
The 2011 Dr. Paul Janssen Award winner will be announced in the second half of 2011.
About The Dr. Paul Janssen Award for Biomedical Research
Established by Johnson & Johnson, The Dr. Paul Janssen Award salutes the most passionate and creative scientists in basic or clinical research whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. The Dr. Paul Janssen Award is named for Dr. Paul Janssen, who founded Janssen Pharmaceutica, N.V. in 1953. Known to his colleagues as “Dr. Paul,” Janssen was one of the 20th century’s most gifted and passionate researchers, a physician-scientist who helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, four of which remain on the World Health Organization’s list of essential medicines. In 1961, Janssen Pharmaceutica, N.V. joined the Johnson & Johnson Family of Companies. Janssen’s legacy continues to inspire Johnson & Johnson and its commitment to finding innovative cures for unmet medical needs. Visit www.pauljanssenaward.com for more information.
About Johnson & Johnson
Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 119,400 employees at more than 250 Johnson & Johnson companies work with partners in healthcare to touch the lives of over a billion people every day, throughout the world.
Contact: | |
Seema Kumar | |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
908-218-6460 or skumar10@its.jnj.com | |
Frederik Wittock | |
Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, N.V. | |
+32 14 60 57 24 or fwittock@its.jnj.com | |
SOURCE Johnson & Johnson
